The Role of Pelvic Node Irradiation in Node Positive Prostate Cancer; the Norfolk and Norwich University Hospital (NNUH) Experience 2011 –2015

Purpose: The role of pelvic nodal irradiation in prostate cancer remains controversial. Nevertheless, many high-risk patients are treated with prostate and pelvis radiotherapy in addition to androgen deprivation therapy (ADT) [1]. A recent retrospective study [2] and data from the UK Stampede control arm [3] suggest that radiotherapy may be of benefit to node positive patients. The aim of our study was to document outcomes in patients with node positive prostate cancer treated with pelvic nodal radiotherapy in a UK cancer centre.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research

Related Links:

Conditions:   Prostate Cancer;   Radical Prostatectomy Intervention:   Combination Product: Microdevice Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 24 May 2020Source: European UrologyAuthor(s): Amar U. Kishan, Tahmineh Romero, Mohammed Alshalalfa, Yang Liu, Phuoc T. Tran, Nicholas G. Nickols, Huihui Ye, Dipti Sajed, Matthew B. Rettig, Robert E. Reiter, Isla P. Garraway, Daniel E. Spratt, Steven J. Freedland, Xin Zhao, Ziwen Li, Matthew Deek, Julie Livingstone, Brandon A. Mahal, Paul L. Nguyen, Felix Y. Feng
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conditions:   Prostate Cancer;   Radical Prostatectomy Intervention:   Combination Product: Microdevice Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Despite the emphasis on randomized data to guide evidence-based practice, there is a notable lack of clinical trials to inform comparative effectiveness in surgical disciplines. Although this is multifactorial in nature, this paucity ultimately reflects the difficulty associated with conducting surgical trials, particularly in settings where event rates are low (eg, lymph node metastasis in M0 renal cell carcinoma) or when long follow-up is required, as with early-stage disease (eg, low-risk prostate cancer).
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2 –3 years. A subgroup of those patients with mC...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Study protocol Source Type: research
o-Hong Chen Enzalutamide is the first second-generation nonsteroidal androgen receptor (AR) antagonist with a strong binding affinity to AR. Most significantly, enzalutamide can prolong not only overall survival time and metastatic free survival time for patients with lethal castration-resistant prostate cancer (CRPC), but also castration-resistant free survival time for patients with castration-sensitive prostate cancer (CSPC). Enzalutamide has thus been approved by the US Food and Drug Administration (FDA) for the treatment of both metastatic (in 2012) and non-metastatic (in 2018) CRPC, as well as CSPC (2019). This i...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
Publication date: Available online 22 May 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Giandomenico Roviello, Benedetta Panella
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 22 May 2020Source: European UrologyAuthor(s): Steven M. Monda, Marc Arnaldo Dall’Era
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Hospitals | Prostate Cancer | Radiology | Study